

Cellnovo joins the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable and announces its 2015/2016 financial calendar

Paris, France, September 22, 2015 – Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announced today that it has been selected to incorporate three indexes of the Euronext CAC family: **CAC® Small, CAC® Mid & Small** and **CAC® All-Tradable**. The company also publishes its financial calendar for the end of 2015 and the year 2016.

Cellnovo member of the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable

The inclusion of Cellnovo shares in these indexes is the result of a share liquidity analysis made by Euronext on the basis of two criteria: amount of capital traded and free float market capitalization. The scope of the liquidity criteria highlights the marked interest from investors for Cellnovo, despite the recent listing of the company. These indexes are used as references by a number of mutual and SICAV open-end investment funds.

Financial calendar

Events	Date *
2015 Q3 sales	Thursday October 22 nd , 2015
2015 FY sales	Wednesday January 20 th , 2016
2015 FY results and 2016 Q1 sales	Wednesday April 27 th . 2016
2016 H1 sales	Wednesday July 20 th , 2016
2016 H1 results	Thursday September 22 nd , 2016
2016 Q3 sales	Thursday October 20 th , 2016

* *Subject to modification. Press releases are published after market closes.*

About Cellnovo

Cellnovo (Euronext, FR 0012633360 - CLNV) is an innovative medical device company specialising in diabetes. Cellnovo has developed and markets the first connected all-in-one diabetes management system based on a patch pump that helps make life easier for patients. With its unique device Cellnovo allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time. The system has CE mark, is reimbursed in most countries and is already being marketed in France and the United Kingdom.

For further information please visit www.cellnovo.com

Contact

Cellnovo

Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relation
 Emmanuel Huynh
cellnovo@newcap.fr
 + 33 1 44 71 94 92

NewCap

Media Relations
 Nicolas Merigeau
cellnovo@newcap.fr
 +33 1 44 71 94 98

Cellnovo is listed on Euronext, Compartment C
 ISIN: FR0012633360 – Ticker: CLNV

